Can a transplant drug help rare muscle disease?
NCT ID NCT02481453
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 33 times
Summary
This study tested the drug rapamycin in 44 adults with Inclusion Body Myositis, a rare muscle disease that causes progressive weakness. The goal was to see if rapamycin could slow the loss of muscle strength. Participants received either rapamycin or a placebo, and their muscle strength and function were measured over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INCLUSION BODY MYOSITIS (IBM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CIC Paris Est _Hôpital Pitié Salpêtrière
Paris, 75651, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.